Palvella director sells 27,500 shares in plan
A Palvella Therapeutics director sold 27,500 PVLA shares under a pre-established Rule 10b5-1 trading plan over three trading days.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Palvella Therapeutics, Inc. (PVLA) director George M. Jenkins reported open-market sales of 27,500 shares of common stock over September 11–15, 2026, at weighted-average prices generally between about $149 and $153 per share. The transactions were effected under a Rule 10b5-1 trading plan adopted on June 12, 2026. Following these transactions, an entity described as Eagles Mere Air Museum Foundation holds 13,516 shares indirectly.
Insider Trade Summary 10b5-1
Net Seller: 27,500 shares
Net Sell
9 txns
Insider
JENKINS GEORGE M
Role
Director
Sold
27,500 shs ($4.17M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1, F2, F9 | 954 | $149.3779 | $143K |
| Sale | Common Stock F1, F2, F10 | 263 | $150.4045 | $40K |
| Sale | Common Stock F1, F2, F11 | 560 | $151.3263 | $85K |
| Sale | Common Stock F1, F2, F6 | 5,632 | $151.4625 | $853K |
| Sale | Common Stock F1, F2, F7 | 6,160 | $152.1159 | $937K |
| Sale | Common Stock F1, F2, F8 | 1,560 | $153.099 | $239K |
| Sale | Common Stock F1, F2, F3 | 6,520 | $150.6189 | $982K |
| Sale | Common Stock F1, F2, F4 | 4,577 | $151.7157 | $694K |
| Sale | Common Stock F1, F2, F5 | 1,274 | $153.0591 | $195K |
| Holding | Common Stock F12 | -- | -- | -- |
Holdings After Transaction:
Common Stock — 160,116 shares (Direct);
Common Stock — 13,516 shares (Indirect, By foundation)
Footnotes (12)
- F1. The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons.
- F2. Any profit required to be disgorged under Section 16 of the Securities Exchange Act of 1934, as amended, with respect to an aggregate of 445 shares sold in the transactions reported on this Form 4 will be disgorged to the Issuer pursuant to applicable requirements.
- F3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $150.23 to $151.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $151.23 to $152.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F5. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $152.42 to $153.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F6. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $150.80 to $151.785, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F7. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $151.80 to $152.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F8. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $152.88 to $153.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F9. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $148.90 to $149.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F10. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $150.0525 to $151.0225, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F11. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $151.16 to $151.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F12. Eagles Mere Air Museum Foundation.
Key Figures
Shares sold: 27,500 shares
Sale dates: September 11–15, 2026
Representative weighted-average prices: $149.38, $150.40, $151.33 per share
+4 more
7 metrics
Shares sold
27,500 shares
Total common shares sold by the director across all reported transactions
Sale dates
September 11–15, 2026
Period over which the reported open-market sales occurred
Representative weighted-average prices
$149.38, $150.40, $151.33 per share
Example weighted-average prices from three of the reported sale blocks
Overall sale price range
$148.90–$153.34 per share
Lowest and highest prices in the ranges disclosed for the sale blocks
Indirect holdings
13,516 shares
Common shares held indirectly "By foundation" after the reported transactions
Section 16 disgorgement shares
445 shares
Aggregate shares whose profit, if required, will be disgorged to the issuer
Rule 10b5-1 plan adoption date
June 12, 2026
Date the trading plan governing these transactions was adopted
Key Terms
Rule 10b5-1 trading plan, Section 16 of the Securities Exchange Act of 1934, as amended, weighted average price, disgorged, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Section 16 of the Securities Exchange Act of 1934, as amended regulatory
"Any profit required to be disgorged under Section 16 of the Securities Exchange Act of 1934, as amended"
weighted average price financial
"The price reported in Column 4 is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
disgorged regulatory
"will be disgorged to the Issuer pursuant to applicable requirements"
insider trading policy regulatory
"and was reviewed and approved in accordance with the Issuer's Insider Trading Policy"
A written set of rules that tells employees, executives and board members what information they may not use to buy or sell a company's stock and when trading is allowed. Think of it as a playbook or house rules that prevent people with secret knowledge from getting an unfair advantage; it matters to investors because it helps protect fair markets, preserves trust in management, and reduces the risk of legal penalties that can hurt a company’s value.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider trading activity did PVLA report for director George M. Jenkins?
Palvella Therapeutics reported that director George M. Jenkins sold 27,500 shares of common stock in open-market transactions on September 11, 14 and 15, 2026, at weighted-average prices in the high-$140s to low-$150s per share.
Was the September 2026 PVLA insider selling done under a Rule 10b5-1 plan?
Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan adopted on June 12, 2026 during an open trading window and reviewed and approved in accordance with Palvella Therapeutics’ insider trading policy.
What Section 16 disgorgement did the PVLA Form 4 disclose?
The filing notes that any profit required to be disgorged under Section 16 of the Exchange Act with respect to an aggregate of 445 shares sold in the reported transactions will be disgorged to Palvella Therapeutics pursuant to applicable requirements.
Are the reported PVLA sale prices exact or averages for each transaction block?
The filing explains that each price in Column 4 is a weighted average price. For each block, shares were sold in multiple transactions within stated price ranges, and detailed trade information is available upon request.
AI-generated analysis. How Rhea-AI works. Not financial advice.
